Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,626 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Genetics Clear all
Completed Phase 2 Interventional Results available

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

NCT03833661
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
Interventions
M7824
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Nov 4, 2026, 10:45 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma

NCT01876303
View directory record Official record
Conditions
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
1,650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Nov 4, 2026, 10:45 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

NCT05926102
View directory record Official record
Conditions
Prostate Cancer
Interventions
Precision screening intervention, Usual care
Genetic · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years to 69 Years · Male only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Nov 4, 2026, 10:45 PM EST
Completed No phase listed Observational

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

NCT00082745
View directory record Official record
Conditions
Childhood Malignant Neoplasm
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 99 Years
Enrollment
3,885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
134
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 102 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Nov 4, 2026, 10:45 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms

NCT01064466
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
ETOPOSIDE - Usual, ETOPOSIDE - Study
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Industry
Eligibility
24 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 4, 2026, 10:45 PM EST
Terminated No phase listed Observational

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

NCT03886753
View directory record Official record
Conditions
ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions
Registry, PK microsampling of blood
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Nov 4, 2026, 10:45 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Genetic Counseling for Menopausal Therapy Decision-Making for Women at Increased Risk for Breast Cancer

NCT00349011
View directory record Official record
Conditions
Menopause
Interventions
Personalized risk assessment, genetic counseling intervention
Procedure
Lead sponsor
Yale University
Other
Eligibility
40 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Nov 4, 2026, 10:45 PM EST
Completed Not applicable Interventional Results available

Molecular-Guided Therapy for Childhood Cancer

NCT02162732
View directory record Official record
Conditions
Neuroblastoma, Medulloblastoma, Glioma, Ependymoma, Choroid Plexus Neoplasms, Craniopharyngioma, Dysembryoplastic Neuroepithelial Tumor, Meningioma, Primitive Neuroectodermal Tumors (PNETs), Germ Cell Tumors, Rhabdomyosarcoma, Non-rhabdomyosarcoma, Ewings Sarcoma, Osteosarcoma, Wilms Tumor, Renal Cell Carcinoma, Malignant Rhabdoid Tumor, Clear Cell Sarcoma, Liver Tumors
Interventions
Guided Therapy
Device
Lead sponsor
Giselle Sholler
Other
Eligibility
13 Months to 21 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
18
States / cities
Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Nov 4, 2026, 10:45 PM EST
Terminated Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

NCT00996892
View directory record Official record
Conditions
Solid Tumors
Interventions
Cobimetinib, Pictilisib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Nov 4, 2026, 10:45 PM EST
Completed Phase 2 Interventional

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

NCT02236195
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Mocetinostat
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Nov 4, 2026, 10:45 PM EST
Recruiting No phase listed Observational

Cardiovascular Multimodality Imaging Study

NCT06610019
View directory record Official record
Conditions
Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy, Cardiac Amyloidosis, Anderson Fabry Disease, Sarcoidosis, Cancer Therapy-related Cardiac Dysfunction, Ventricular Arrythmia, Heart Failure
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 4, 2026, 10:45 PM EST
Completed Phase 1Phase 2 Interventional Results available

Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex

NCT00411619
View directory record Official record
Conditions
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Interventions
Everolimus
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Nov 4, 2026, 10:45 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Model for Genetic Susceptibility: Melanoma

NCT00591500
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
4,082 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 4, 2026, 10:45 PM EST
Completed Not applicable Interventional

Scalable Communication Modalities for Returning Genetic Research Results

NCT04407611
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer, Lynch Syndrome
Interventions
Online modality, Genetic counselor follow-up
Behavioral
Lead sponsor
Boston University
Other
Eligibility
40 Years and older · Female only
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 4, 2026, 10:45 PM EST
Completed Phase 2 Interventional Results available

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

NCT00301834
View directory record Official record
Conditions
Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes, Severe Congenital Neutropenia
Interventions
alemtuzumab, busulfan, cyclosporine, fludarabine phosphate, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
San Francisco, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Nov 4, 2026, 10:45 PM EST
Recruiting No phase listed Observational

Decoupling Immunotherapy Toxicity and Cancer Response

NCT07382752
View directory record Official record
Conditions
Tumor, Cardiovascular
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 4, 2026, 10:45 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer

NCT02786147
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer
Interventions
Breast Cancer Genetics Referral Screening Tool 3.0, Standard Handout, Physician Notification, Automatic Follow-Up by Genetic Counseling Staff
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Nov 4, 2026, 10:45 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial

NCT05361811
View directory record Official record
Conditions
Neurofibromatosis 1, Noonan Syndrome, Legius Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome
Interventions
Waitlist, ACT Intervention
Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 4, 2026, 10:45 PM EST
Not listed Phase 2 Interventional

Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

NCT03831698
View directory record Official record
Conditions
Colorectal Cancer, Lynch Syndrome
Interventions
Omega-3 fatty acid ethyl esters (2 gram)
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Nov 4, 2026, 10:45 PM EST
Completed Phase 1 Interventional

B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency

NCT00024934
View directory record Official record
Conditions
IgA Deficiency
Interventions
B-Lymphocyte Stimulator (BLyS)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Nov 4, 2026, 10:45 PM EST
Recruiting No phase listed Observational

Barriers and Facilitators of Parent-Child Communication in Children With Cancer Predisposition

NCT05849155
View directory record Official record
Conditions
Genetic Predisposition
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
10 Years to 24 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 4, 2026, 10:45 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network

NCT05627219
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Training and Education, Educational Intervention, Discussion
Behavioral · Other · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 4, 2026, 10:45 PM EST
Completed Phase 1 Interventional

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

NCT01226316
View directory record Official record
Conditions
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive
Interventions
AZD5363
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • West Hollywood, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Nov 4, 2026, 10:45 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Cancer of the Pancreas Screening Study (CAPS 3)

NCT00438906
View directory record Official record
Conditions
Pancreatic Neoplasm, Peutz-Jeghers Syndrome
Interventions
Biopsy, Fine Needle Aspiration (FNA), Secretin (human synthetic) - ChiRhoClin
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Nov 4, 2026, 10:45 PM EST